Osteoclast differentiation from monocyte/macrophage precursors
Materials Required
Principle
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates[1][2][3][4][5][6]. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation[1][2][3][4]. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity[5][6][7][8].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use monocyte/macrophage precursors from human peripheral blood mononuclear cells, purified human CD14+ or CD16− monocytes, human bone marrow monocytes, mouse bone marrow-derived macrophages, or RAW264.7 macrophage-like cells when the experimental question matches the selected model[5][6][7][9][10][11][12].
• Use M-CSF to support precursor survival and macrophage/osteoclast-precursor expansion, and use RANKL to induce terminal osteoclast differentiation; reported human cultures commonly used M-CSF with RANKL for approximately 9-14 days, while mouse BMM and RAW264.7 systems often generated osteoclasts within about 4-7 days depending on cell source and seeding density[5][6][7][8][12][13].
• Use standard cell-culture medium and serum only as reported by the selected source protocol, because serum conditions influence osteoclast yield and activity in human PBMC cultures[6][7][13].
• Use dentin slices, bovine cortical bone slices, human bone slices, or mineralized calcium phosphate/osteo-assay surfaces when functional resorption is the intended endpoint[5][6][7][8].
• Use TRAP staining to identify osteoclast-lineage cells and quantify TRAP-positive multinucleated cells; published protocols commonly count multinucleated TRAP-positive cells using thresholds of more than two nuclei or three or more nuclei per cell, so the threshold should be predefined and kept constant within an experiment[5][6][8][13].
• Use phalloidin-based F-actin staining with nuclear counterstaining when actin-ring formation and multinucleation are required readouts[7][8][13].
• Use antibodies or assays for osteoclast markers such as integrin β3, cathepsin K, calcitonin receptor, or NFATc1 only when marker validation is part of the study design[6][9][10][13].
• Use sterile tissue-culture plates for differentiation, 96-well plates or multiwell formats for TRAP and resorption assays, phase-contrast or bright-field microscopy for morphology and TRAP counting, fluorescence microscopy for F-actin/nuclear imaging, and scanning electron microscopy or light microscopy for resorption-pit assessment depending on the substrate and protocol[5][6][7][8][13].
• Use M-CSF to support precursor survival and macrophage/osteoclast-precursor expansion, and use RANKL to induce terminal osteoclast differentiation; reported human cultures commonly used M-CSF with RANKL for approximately 9-14 days, while mouse BMM and RAW264.7 systems often generated osteoclasts within about 4-7 days depending on cell source and seeding density[5][6][7][8][12][13].
• Use standard cell-culture medium and serum only as reported by the selected source protocol, because serum conditions influence osteoclast yield and activity in human PBMC cultures[6][7][13].
• Use dentin slices, bovine cortical bone slices, human bone slices, or mineralized calcium phosphate/osteo-assay surfaces when functional resorption is the intended endpoint[5][6][7][8].
• Use TRAP staining to identify osteoclast-lineage cells and quantify TRAP-positive multinucleated cells; published protocols commonly count multinucleated TRAP-positive cells using thresholds of more than two nuclei or three or more nuclei per cell, so the threshold should be predefined and kept constant within an experiment[5][6][8][13].
• Use phalloidin-based F-actin staining with nuclear counterstaining when actin-ring formation and multinucleation are required readouts[7][8][13].
• Use antibodies or assays for osteoclast markers such as integrin β3, cathepsin K, calcitonin receptor, or NFATc1 only when marker validation is part of the study design[6][9][10][13].
• Use sterile tissue-culture plates for differentiation, 96-well plates or multiwell formats for TRAP and resorption assays, phase-contrast or bright-field microscopy for morphology and TRAP counting, fluorescence microscopy for F-actin/nuclear imaging, and scanning electron microscopy or light microscopy for resorption-pit assessment depending on the substrate and protocol[5][6][7][8][13].
Experimental Procedure
• Isolate human PBMCs from anticoagulated blood by density-gradient centrifugation when using peripheral blood precursors; published human osteoclast protocols then use either total PBMCs, monocyte-enriched cells, CD14+ monocytes, or CD16− monocytes as osteoclast precursors[7][9][10][11][14].
• For mouse primary cultures, flush marrow from long bones, culture marrow cells with M-CSF to obtain bone marrow-derived macrophages, and then induce osteoclastogenesis with RANKL plus M-CSF[5][8][12].
• Seed cells at a density supported by the selected model and assay format; examples include human PBMC systems optimized over several PBMC densities in 96-well plates, human monocyte cultures treated with M-CSF and RANKL for 14 days, and RAW264.7 cultures in which seeding density strongly affected RANKL-induced osteoclast formation[6][7][12][13].
• Prepare parallel culture surfaces for differentiation-only readouts and functional resorption readouts; use plastic for TRAP and morphology, and dentin, bone, or mineralized substrates for resorption analysis[5][6][7][8].
• For human peripheral blood or bone marrow monocyte cultures, culture precursors with M-CSF and RANKL, replacing medium and cytokines according to the cited source protocol, and analyze differentiation after approximately 9-14 days when TRAP-positive multinucleated cells and resorption activity are expected[6][7][9][13].
• For mouse BMM cultures, expand marrow-derived macrophages with M-CSF, seed adherent macrophages, add RANKL with M-CSF, and culture until large TRAP-positive multinucleated osteoclasts appear, commonly within approximately one week[5][8][12].
• For RAW264.7 cultures, induce osteoclast-like differentiation primarily with RANKL, because RAW264.7 cells can differentiate in response to RANKL and published optimization studies found that RANKL concentration, stimulation timing, and cell density strongly affect osteoclast formation[12][13].
• At the endpoint, fix cells and perform TRAP staining for differentiation analysis; count TRAP-positive multinucleated cells using the predefined nuclear threshold and report the threshold with the result[5][6][8][13].
• For functional analysis, culture cells on dentin, bone, or mineralized substrate, remove cells after differentiation, image the resorbed surface, and quantify resorption area or pit number as the functional osteoclast readout[5][6][7][8].
• For cytoskeletal maturation, fix cultures, stain F-actin and nuclei, and assess whether multinucleated cells form actin rings, because actin-ring formation is associated with mature osteoclast resorptive organization[7][8][13].
• Report osteoclast differentiation as TRAP-positive multinucleated cells per well, per defined microscopic field, or per culture area, and report functional activity as resorbed area, pit number, or percentage resorbed surface when resorption substrates are used[5][6][7][8][13].
• Include a negative control without RANKL, because cultures lacking osteoclastogenic growth factors generally show absent, occasional, or low osteoclast formation depending on precursor source; include M-CSF plus RANKL as the positive induction condition[6][7][9][13].
• Interpret TRAP staining together with multinucleation and resorption, because total TRAP area or TRAP activity alone may not correlate with bone-resorbing function in human primary osteoclast assays[6].
• Use biological replicates from independent donors or animals and technical replicate wells when comparing conditions, because donor source, monocyte subset, tissue source, and cell density can alter osteoclast yield and resorptive function[6][7][9][10][13].
• For mouse primary cultures, flush marrow from long bones, culture marrow cells with M-CSF to obtain bone marrow-derived macrophages, and then induce osteoclastogenesis with RANKL plus M-CSF[5][8][12].
• Seed cells at a density supported by the selected model and assay format; examples include human PBMC systems optimized over several PBMC densities in 96-well plates, human monocyte cultures treated with M-CSF and RANKL for 14 days, and RAW264.7 cultures in which seeding density strongly affected RANKL-induced osteoclast formation[6][7][12][13].
• Prepare parallel culture surfaces for differentiation-only readouts and functional resorption readouts; use plastic for TRAP and morphology, and dentin, bone, or mineralized substrates for resorption analysis[5][6][7][8].
• For human peripheral blood or bone marrow monocyte cultures, culture precursors with M-CSF and RANKL, replacing medium and cytokines according to the cited source protocol, and analyze differentiation after approximately 9-14 days when TRAP-positive multinucleated cells and resorption activity are expected[6][7][9][13].
• For mouse BMM cultures, expand marrow-derived macrophages with M-CSF, seed adherent macrophages, add RANKL with M-CSF, and culture until large TRAP-positive multinucleated osteoclasts appear, commonly within approximately one week[5][8][12].
• For RAW264.7 cultures, induce osteoclast-like differentiation primarily with RANKL, because RAW264.7 cells can differentiate in response to RANKL and published optimization studies found that RANKL concentration, stimulation timing, and cell density strongly affect osteoclast formation[12][13].
• At the endpoint, fix cells and perform TRAP staining for differentiation analysis; count TRAP-positive multinucleated cells using the predefined nuclear threshold and report the threshold with the result[5][6][8][13].
• For functional analysis, culture cells on dentin, bone, or mineralized substrate, remove cells after differentiation, image the resorbed surface, and quantify resorption area or pit number as the functional osteoclast readout[5][6][7][8].
• For cytoskeletal maturation, fix cultures, stain F-actin and nuclei, and assess whether multinucleated cells form actin rings, because actin-ring formation is associated with mature osteoclast resorptive organization[7][8][13].
• Report osteoclast differentiation as TRAP-positive multinucleated cells per well, per defined microscopic field, or per culture area, and report functional activity as resorbed area, pit number, or percentage resorbed surface when resorption substrates are used[5][6][7][8][13].
• Include a negative control without RANKL, because cultures lacking osteoclastogenic growth factors generally show absent, occasional, or low osteoclast formation depending on precursor source; include M-CSF plus RANKL as the positive induction condition[6][7][9][13].
• Interpret TRAP staining together with multinucleation and resorption, because total TRAP area or TRAP activity alone may not correlate with bone-resorbing function in human primary osteoclast assays[6].
• Use biological replicates from independent donors or animals and technical replicate wells when comparing conditions, because donor source, monocyte subset, tissue source, and cell density can alter osteoclast yield and resorptive function[6][7][9][10][13].
Troubleshooting
Problem: Few or no multinucleated TRAP-positive osteoclasts form.
• Possible cause: RANKL is absent, insufficient, or applied under suboptimal cell-density conditions.• Literature-supported solution: Include a RANKL-containing positive-control condition, keep RANKL/M-CSF conditions matched to the selected source protocol, and optimize seeding density within the reported model because RANKL and density strongly affect osteoclastogenesis[1][2][5][12][13].
Problem: TRAP-positive cells form, but resorption is weak or absent.
• Possible cause: TRAP staining detects differentiation but does not prove bone-resorbing function.• Literature-supported solution: Add a functional endpoint using dentin, bone, or mineralized substrate and quantify pit number or resorbed area rather than relying on total TRAP signal alone[5][6][7][8].
Problem: Human donor cultures show variable osteoclast yield.
• Possible cause: Osteoclastogenic potential differs by precursor source and monocyte subset.• Literature-supported solution: Record whether cells are PBMCs, CD14+ cells, CD16− monocytes, bone marrow monocytes, or cord blood monocytes, and use independent donor biological replicates[7][9][10][11].
Problem: RAW264.7 cultures produce inconsistent osteoclast numbers.
• Possible cause: RANKL dose, stimulation timing, and seeding density affect RAW264.7 osteoclastogenesis.• Literature-supported solution: Standardize RAW264.7 passage handling, seeding density, RANKL stimulation timing, and culture duration within the reported optimization range[12][13].
References:
- [1]. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165-176. [Content Brief]
- [2]. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597-3602. [Content Brief]
- [3]. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998;253(2):395-400. [Content Brief]
- [4]. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999;96(7):3540-3545. [Content Brief]
- [5]. Takahashi N, et al. Generation of osteoclasts in vitro, and assay of osteoclast activity. Methods Mol Med. 2007;135:285-301. [Content Brief]
- [6]. Susa M, et al. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med. 2004;2(1):6. [Content Brief]
- [7]. Vuoti E, et al. Osteoclastogenesis of human peripheral blood, bone marrow, and cord blood monocytes. Sci Rep. 2023;13(1):3763. [Content Brief]
- [8]. Dai Q, Xie F, Han Y, Ma X, Zhou S, Jiang L, et al. A RANKL-based osteoclast culture assay of mouse bone marrow to investigate the role of mTORC1 in osteoclast formation. J Vis Exp. 2018;(133):56468. [Content Brief]
- [9]. Neale SD, et al. Osteoclast differentiation from circulating mononuclear precursors in Paget’s disease is hypersensitive to 1,25-dihydroxyvitamin D3 and RANKL. Bone. 2000;27(3):409-416. [Content Brief]
- [10]. Komano Y, et al. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther. 2006;8(5):R152. [Content Brief]
- [11]. Massey HM, et al. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol. 1999;106(1):167-170. [Content Brief]
- [12]. Nguyen J, et al. Factors that affect the osteoclastogenesis of RAW264.7 cells. J Biochem Anal Stud. 2017;2(1):1-7.
- [13]. Cheng Y, Huang L, Wang Y, Huo Q, Shao Y, Bao H, et al. Evaluation of culture conditions for osteoclastogenesis in RAW264.7 cells. PLoS One. 2022;17(11):e0277871. [Content Brief]
- [14]. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest Suppl. 1968;97:77-89. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail